Endocrinization of FGF1 produces a neomorphic and potent insulin sensitizer (original) (raw)

References

  1. Beenken, A. & Mohammadi, M. The FGF family: biology, pathophysiology and therapy. Nature Rev. Drug Discov. 8, 235–253 (2009)
    Article CAS Google Scholar
  2. Itoh, N. & Ornitz, D. M. Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. J. Biochem. 149, 121–130 (2011)
    Article CAS Google Scholar
  3. Jonker, J. W. et al. A PPARγ–FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasis. Nature 485, 391–394 (2012)
    Article CAS Google Scholar
  4. Sun, K. & Scherer, P. E. The PPARγ–FGF1 axis: an unexpected mediator of adipose tissue homeostasis. Cell Res. 22, 1416–1418 (2012)
    Article CAS Google Scholar
  5. Lehrke, M. & Lazar, M. A. The many faces of PPARγ. Cell 123, 993–999 (2005)
    Article CAS Google Scholar
  6. Kharitonenkov, A. et al. FGF-21 as a novel metabolic regulator. J. Clin. Invest. 115, 1627–1635 (2005)
    Article CAS Google Scholar
  7. Dutchak, P. A. et al. Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones. Cell 148, 556–567 (2012)
    Article CAS Google Scholar
  8. Zinn, K. R. et al. Imaging Tc-99m-labeled FGF-1 targeting in rats. Nucl. Med. Biol. 27, 407–414 (2000)
    Article CAS Google Scholar
  9. Lee, J. & Blaber, M. The interaction between thermodynamic stability and buried free cysteines in regulating the functional half-life of fibroblast growth factor-1. J. Mol. Biol. 393, 113–127 (2009)
    Article CAS Google Scholar
  10. Wu, A. L. et al. Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1. Sci. Transl. Med. 3, 113ra126 (2011)
    Article Google Scholar
  11. Li, A. J., Tsuboyama, H., Komi, A., Ikekita, M. & Imamura, T. Strong suppression of feeding by a peptide containing both the nuclear localization sequence of fibroblast growth factor-1 and a cell membrane-permeable sequence. Neurosci. Lett. 255, 41–44 (1998)
    Article CAS Google Scholar
  12. Suzuki, S. et al. Feeding suppression by fibroblast growth factor-1 is accompanied by selective induction of heat shock protein 27 in hypothalamic astrocytes. Eur. J. Neurosci. 13, 2299–2308 (2001)
    Article CAS Google Scholar
  13. Sasaki, K. et al. Effects of fibroblast growth factors and related peptides on food intake by rats. Physiol. Behav. 56, 211–218 (1994)
    Article CAS Google Scholar
  14. Wei, W. et al. Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor γ. Proc. Natl Acad. Sci. USA 109, 3143–3148 (2012)
    Article ADS CAS Google Scholar
  15. Holland, W. L. et al. An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice. Cell Metab. 17, 790–797 (2013)
    Article CAS Google Scholar
  16. Lin, Z. et al. Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab. 17, 779–789 (2013)
    Article ADS CAS Google Scholar
  17. Hevener, A. L. et al. Muscle-specific Pparg deletion causes insulin resistance. Nature Med. 9, 1491–1497 (2003)
    Article CAS Google Scholar
  18. Van Dijk, T. H. et al. Quantification of hepatic carbohydrate metabolism in conscious mice using serial blood and urine spots. Anal. Biochem. 322, 1–13 (2003)
    Article CAS Google Scholar

Download references

Acknowledgements

We thank L. Chong, J. Alvarez, S. Kaufman, B. Collins, X. Zhao, S. Liu, A. Jurdzinski, A. Bleeker, K. Bijsterveld, D. Oh and G. Bandyopadhyay for technical assistance, and L. Ong and C. Brondos for administrative assistance. Computed tomography was performed at the Veterans Medical Research Foundation. R.M.E. is a Howard Hughes Medical Institute Investigator at the Salk Institute and March of Dimes Chair, and is supported by National Institutes of Health (NIH) grants (DK057978, DK090962, HL088093, HL105278 and ES010337), the Glenn Foundation for Medical Research, the Leona M. and Harry B. Helmsley Charitable Trust, Ipsen/Biomeasure, the California Institute for Regenerative Medicine and The Ellison Medical Foundation. C.L. and M.D. are funded by the National Health and Medical Research Council (grants 512354, 632886 and 1043199); J.W.J. by the European Research Council (grant IRG-277169), the Human Frontier Science Program (CDA00013/2011-C), the Netherlands Organisation for Scientific Research (VIDI grant 016.126.338), the Dutch Digestive Foundation (grant WO 11-67) and the Dutch Diabetes Foundation (grant 2012.00.1537); J.M.O. by NIH grants (DK-033651, DK-074868, T32-DK-007494, DK-063491 and P01-DK054441-14A1) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development/NIH through cooperative agreement of U54-HD-012303-25 as part of the specialized Cooperative Centers Program in Reproduction and Infertility Research; M.M. by the National Institute of Dental and Craniofacial Research grant (DE13686); and M.A. by an F32 Ruth L. Kirschstein National Research Service Award (National Institute of Diabetes and Digestive and Kidney Diseases).

Author information

Author notes

  1. Zhifeng Huang
    Present address: Present address: School of Pharmacy, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China.,
  2. Jae Myoung Suh and Johan W. Jonker: These authors contributed equally to this work.

Authors and Affiliations

  1. Gene Expression Laboratory, Salk Institute for Biological Studies, La Jolla, 92037, California, USA
    Jae Myoung Suh, Maryam Ahmadian, Eiji Yoshihara, Weiwei Fan, Yun-Qiang Yin, Ruth T. Yu, Annette R. Atkins, Michael Downes & Ronald M. Evans
  2. Departments of Pediatrics and Laboratory Medicine, Center for Liver, Digestive and Metabolic Diseases, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands,
    Johan W. Jonker, Weilin Liu, Theo H. van Dijk & Rick Havinga
  3. Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, 10016, New York, USA
    Regina Goetz, Zhifeng Huang & Moosa Mohammadi
  4. Department of Medicine, Division of Endocrinology and Metabolism, University of California at San Diego, La Jolla, 92093, California, USA
    Denise Lackey, Olivia Osborn & Jerrold M. Olefsky
  5. The Storr Liver Unit, Westmead Millennium Institute and University of Sydney, Westmead Hospital, Westmead, 2145, New South Wales, Australia
    Christopher Liddle
  6. Howard Hughes Medical Institute, Salk Institute for Biological Studies, La Jolla, 92037, California, USA
    Ronald M. Evans

Authors

  1. Jae Myoung Suh
    You can also search for this author inPubMed Google Scholar
  2. Johan W. Jonker
    You can also search for this author inPubMed Google Scholar
  3. Maryam Ahmadian
    You can also search for this author inPubMed Google Scholar
  4. Regina Goetz
    You can also search for this author inPubMed Google Scholar
  5. Denise Lackey
    You can also search for this author inPubMed Google Scholar
  6. Olivia Osborn
    You can also search for this author inPubMed Google Scholar
  7. Zhifeng Huang
    You can also search for this author inPubMed Google Scholar
  8. Weilin Liu
    You can also search for this author inPubMed Google Scholar
  9. Eiji Yoshihara
    You can also search for this author inPubMed Google Scholar
  10. Theo H. van Dijk
    You can also search for this author inPubMed Google Scholar
  11. Rick Havinga
    You can also search for this author inPubMed Google Scholar
  12. Weiwei Fan
    You can also search for this author inPubMed Google Scholar
  13. Yun-Qiang Yin
    You can also search for this author inPubMed Google Scholar
  14. Ruth T. Yu
    You can also search for this author inPubMed Google Scholar
  15. Christopher Liddle
    You can also search for this author inPubMed Google Scholar
  16. Annette R. Atkins
    You can also search for this author inPubMed Google Scholar
  17. Jerrold M. Olefsky
    You can also search for this author inPubMed Google Scholar
  18. Moosa Mohammadi
    You can also search for this author inPubMed Google Scholar
  19. Michael Downes
    You can also search for this author inPubMed Google Scholar
  20. Ronald M. Evans
    You can also search for this author inPubMed Google Scholar

Contributions

J.M.S., J.W.J. M.D. and R.M.E. designed and supervised the research. J.M.S., J.W.J., M.A., R.G., D.L., O.O., Z.H., W.L., E.Y., T.H.D., R.H., W.F., Y.-Q.Y. and A.R.A. performed research. J.M.S., J.W.J., M.A., R.T.Y., C.L., A.R.A., J.M.O., M.M., M.D. and R.M.E. analysed data. J.M.S., J.W.J., M.A., R.G., A.R.A., M.D. and R.M.E. wrote the manuscript.

Corresponding authors

Correspondence toMichael Downes or Ronald M. Evans.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Extended data figures and tables

Extended Data Figure 1 Acute rFGF1 injection lowers blood glucose levels and reduces food intake.

a–c, Blood glucose levels in ob/ob mice after subcutaneous (sc, n = 3) or intraperitoneal (ip, n = 3) injection of rFGF1 (a), intravenous (iv) injection of rFGF1 (n = 6) or control vehicle (n = 5) (b), or subcutaneous injection of rFGF1 premixed with heparin (1.5 mg kg−1, n = 3) (c). d, Serum insulin levels 24 h after rFGF1 treatment under ad libitum fed or fasting conditions in chow-fed C57BL/6J mice (n = 10). e, Blood glucose levels in fasted, chow-fed mice after treatment with rFGF1 (n = 8). f, Food intake during 24 h after injection of rFGF1 in chow-fed C57BL/6J mice (n = 8). g–i, Food intake during indicated times after injection of rFGF1 in ob/ob (n = 6) (g), db/db (n = 3) (h) and DIO (n = 6) (i) mice. Control PBS (open bar) or murine rFGF1 (0.5 mg kg−1; filled bar) were injected subcutaneously to ad libitum fed mice unless otherwise noted. Values are means and s.e.m. Statistics by two-tailed _t_-test: *P < 0.05; **P < 0.01.

Extended Data Figure 2 Chronic administration of rFGF1 lowers blood glucose independently of food intake and metabolic hormones.

a–c, MRI analyses of fat (a) and lean mass content (b) at indicated days, and food intake (c) during chronic administration of control vehicle (n = 6) or rFGF1 (n = 8) in ob/ob mice. d, Random-fed blood glucose of a pair-fed cohort of ob/ob mice (red line, filled triangles, n = 12) plotted alongside blood glucose trends during chronic administration of control vehicle (black line, open squares, n = 6) or rFGF1 in ob/ob mice (black line, filled squares; n = 8). Pair-fed cohort food intake was restricted to equal the food intake of rFGF1-injected ob/ob mice throughout the 5-week trial. e–g, Serum cholesterol (e), free fatty acids (f) and metabolic hormone levels (g) after 5-week administration of control PBS or rFGF1 in ob/ob mice (n = 4). h–j, Body weight (h), tissue mass analyses (i) and food intake (j) of DIO mice after 4 weeks of rFGF1 treatment (n = 6). All injections were performed subcutaneously with control vehicle (PBS, open bars or symbols) or murine rFGF1 (0.5 mg kg−1; filled bars or symbols) to ad libitum fed mice every 48 h throughout chronic administration trials. Values are means and s.e.m. Statistics by two-tailed _t_-test: *P < 0.05; **P < 0.01.

Extended Data Figure 3 rFGF1 does not stimulate insulin secretion and chronic administration reduces systemic inflammation.

a, Glucose-stimulated insulin secretion (basal; 3 mM glucose; stimulated, 20 mM glucose) of ob/ob islets after 1 h pretreatment with control PBS (open bars) or rFGF1 (10 ng ml−1, filled bars; n = 6). b, c, Time course of serum insulin (b) and blood glucose (c) levels in ob/ob mice after a single rFGF1 injection (0.2 mg kg−1 intravenously; n = 8). d, Serum cytokines in ob/ob mice after 5 weeks of subcutaneous administration of control vehicle (PBS, open bars; n = 4) or rFGF1 (0.5 mg kg−1 every other day, filled bars; n = 6) Values are means and s.e.m. Statistics by two-tailed _t_-test: *P < 0.05; **P < 0.01.

Extended Data Figure 4 rFGF1 is an insulin sensitizer and does not affect bone morphology.

a–d, Steady-state glucose infusion rate (a), hepatic inflammation-related gene expression (b), glucose tolerance tests (c) and body weights (d) of DIO mice after 3 weeks of administration of control PBS (n = 11) or rFGF1 (0.5 mg kg−1 every other day; n = 9). e, f, Basal hepatic glucose production (e) and basal and clamped serum insulin concentrations (f) measured during hyperinsulinaemic–euglycaemic clamp studies of DIO mice after 3 weeks of administration of control PBS (n = 11) or rFGF1 (n = 9). g, h, Insulin induced phosphorylation of AKT in liver (g) and muscle tissues (h) of DIO mice after 3 weeks of administration of control PBS (n = 11) or rFGF1 (n = 12). i–n, Food intake (i), carbon dioxide production (j), heat production (k), total activity (l), respiratory exchange ratio (m) and oxygen consumption (n) of chronically rFGF1-treated DIO mice (3 weeks of treatment with control PBS (blue symbols, n = 4) or rFGF1 (red symbols, n = 4) measured in metabolic cages. o, Representative haematoxylin and eosin staining of inguinal white adipose tissue from DIO mice after 4 weeks of administration of control PBS (n = 6) or rFGF1 (n = 6). p, Serum creatine kinase levels in chronically rFGF1-treated ob/ob mice (n = 4). q, r, Bone mineral density (q) and trabecular bone thickness (Tb Th), trabecular bone space (Tb Sp) and cortical bone thickness (C Th) (r) in 4-week treated DIO mice analysed by micro-computed tomography (n = 6). s, Total and high-molecular-weight (HMW) serum adiponectin levels in ob/ob mice after 4 weeks of rFGF1 injections every 48 h (n = 4). Control vehicle (PBS, open bar), rFGF1 (0.5 mg kg−1 subcutaneously; filled bars). Scale bar, 100 μm. Values are means and s.e.m. Statistics by two-tailed _t_-test: *P < 0.05; **P < 0.01; ***P < 0.005; ****P < 0.001.

Extended Data Figure 5 Binding affinities of rFGF1 and rFGF1ΔNT to FGFRs.

Removal of the N terminus from FGF1 reduces the ligand’s binding affinity for FGFRs. a, Overlays of SPR sensorgrams of FGF1 binding to the ligand-binding domain of FGFRs and fitted saturation binding curves. Equilibrium dissociation constants (_K_d values) were derived from the saturation binding curves. b, Overlays of SPR sensorgrams of FGF1ΔNT binding to the ligand-binding domain of FGFRs. Where possible, _K_d values were calculated from fitted saturation binding curves.

Extended Data Figure 6 rFGF1 and rFGF1ΔNT signal through FGFR1 in a dose-dependent manner.

a, Western blot showing intracellular signalling in serum-starved HEK293 cells after a 15-min treatment with the indicated concentrations of PBS, rFGF1ΔNT or rFGF1. b, Dose response of glucose-lowering effects of subcutaneously delivered rFGF1ΔNT (striped bars) in comparison with rFGF1 (filled bars) in 12-week-old ob/ob mice (n = 8). c, Food intake in DIO mice during a 24 h period after injection of control PBS (open bar), rFGF1 (0.5 mg kg−1 subcutaneously; filled bars) or rFGF1ΔNT (0.5 mg kg−1 subcutaneously; striped bar, n = 10). d, Blood glucose levels in high-fat-diet-fed (8 months) Fgfr1 fl/fl (WT, n = 5) and aP2-Cre;Fgfr1 fl/fl (R1 knockout (KO), n = 4) mice at 0 h (open bars) and 24 h (filled bars) after treatment with rFGF1ΔNT (0.5 mg kg−1 subcutaneously). e, Western blot showing intracellular signalling in serum-starved HEK293 cells after a 15-min treatment with PBS or 10 ng ml−1 rFGF1, two independent preparations of rFGF1ΔNT, and rFGF1ΔNT2. f, Blood glucose levels in ob/ob mice at 0 h (open bars) and 24 h (filled bars) after treatment with rFGF1ΔNT and rFGF1ΔNT2 (0.5 mg kg−1 subcutaneously; n = 2). Gel images are representative of at least three biological replicates. Values are means and s.e.m. Statistics by two-tailed _t_-test: *P < 0.05; ***P < 0.005.

Extended Data Table 1 Metabolic parameters of ob/ob mice chronically treated with rFGF1

Full size table

PowerPoint slides

Rights and permissions

About this article

Cite this article

Suh, J., Jonker, J., Ahmadian, M. et al. Endocrinization of FGF1 produces a neomorphic and potent insulin sensitizer.Nature 513, 436–439 (2014). https://doi.org/10.1038/nature13540

Download citation